ALK and peritoneal mesothelioma: Finally, a growing body of evidence demonstrates that pediatric patients affected by peritoneal mesothelioma may have ALK-rearranged tumors that may have prolonged clinical benefit from the administration of crizotinib or ceritinib, lasting up to 10 years in the case of a girl treated with crizotinib [67,68].